Supplementary Materials: Cell Type-Specific Modulation of Respiratory Chain Supercomplex Organization

Dayan Sun, Bin Li, Ruyi Qiu, Hezhi Fang and Jianxin Lyu



Figure S1. Organization of respiratory chain supercomplex (**A**) In-gel activity assay of complexes I and IV from the liver of C57BL/6J mice; (**B**) Sequence analysis of Cox7a2l allele in C57BL/6J mice with following primers: forward, 5'-GCTGTCTTCAGACACTCCAGAAGAGG-3'; reverse, 5'-CAAAG TGAACCAGTCCTCCACAGG-3'; (**C**,**D**) BN-PAGE/immunoblot analysis of C2C12 (**C**) and 143B cells (**D**) solubilized with digitonin at ratios of 4, 6, and 8 g/g digitonin/protein (**E**) BN-PAGE/IB analysis of mitochondrial protein extracted from 143B cybrids of three different mitochondrial DNA background (haplogroup B4, D4, and F2) with digitonin at a ratio of 6 g/g digitonin/protein. Blots were probed with anti-Grim19, anti-Core2, and anti-COX IV antibodies; Blots were probed with a red dotted line.



Figure S2. 2D BN/SDS-PAGE and western blotting of respiratory complexes in mitochondria prepared with digitonin from 143B cells (**A**) and HIB1B cells (**B**). The blots were probed with anti-Grim19, anti-Core2, and anti-COX IV, respectively. The LSC is indicated with a dotted line.



Figure S3. BN-PAGE and western blot analysis of mitochondrial protein from digitonin-permeabilized cells from immortalized lymphoblastoid cell lines derived from three healthy subjects. The blots were probed with anti-Grim19, anti-Core2, and anti-COX IV.



Figure S4. Relative mtDNA copy number of HIB1B cells after 0 and 72 h of treatment with chloramphenicol (CAP). NS, not significance



Figure S5. (**A**) HIB1B and (**B**) C2C12 cells were treated with 40 µg/mL chloramphenicol (CAP) for 4–5 days; cell pellets were collected after drug removal at 0, 4, 8, 12, 24, and 48 h. BN-PAGE and western blot analysis of whole-cell lysates from digitonin-permeabilized cells. The blots were probed with anti-Core2. The integrated optical density (IOD) of each band was determined and is indicated in the figure; (**C**) HIB1B and (**D**) C2C12 cells were treated with CAP for 24 h. BN-PAGE and western blot analysis of digitonin-treated whole-cell lysates. Blots were probed with anti-Core2. Because of large SDs, results are representative of three independent experiments.

| | G131S |
|----------|---|
| Bos | WASNSKYALIGALRAVAQTISYEVTLAIILLSVLLMSGS |
| Sus | WASNSKYALIGALRAVAQTISYEVTLAIILLSVLLMNGS |
| Ursus | WASNSKYALIGALRAVAQTISYEVTLAIILLSVLLMNGS |
| Dugong | WASNSKYALIGALRAVAQTISYEVSLAIILLPTMLMNGS |
| Macropus | WASNSKYALIGALRAVAQTISYEVTLAIILLSIMLINGS |
| Tarsius | WASNSKYALIGALRAVAQTISYEVTLAIILLAILLMSGS |
| Gorilla | WASNSNYALIGALRAVAQTISYEVTLAIILLSTLLMNGS |
| Pan | WASNSNYALIGALRAVAQTISYEVTLAIILLSTLLMSGS |
| Cebus | WASNSNYALIGALRAVAQTISYEVTLAIILLSTLLMSGS |

Figure S6. Conservation analysis of the m.3697G>A transition in the MT-ND1 gene (G131S substitution). G, Gly; S, Ser.



Figure S7. Next-generation sequencing of MT-ND1 gene from the blood of patient 1 (indicated by a black arrow) (total reads of 3697 in next-generation sequencing: 3322; G = 0; A = 3322). Blood from the mother of the patient were Sanger sequenced in the gene of MT-ND1 (indicated by a red arrow).



Figure S8. PCR-RFLP analysis of MT-ND1 sequences from L and H cells using *Hha*I. Fragment (832 bp) of L cells without m.3697G>A was cut into two small fragments of 528 bp and 304 bp; Fragment of H cells with a homoplasmic m.3697G>A was cut into three small fragments of 528 bp, 270 bp, and 34 bp. M: DNA marker.



Figure S9. Whole cell of clones L and H were solubilized with RIPA buffer and subjected to SDS-PAGE and western blot analysis. The blots were probed with anti-Grim19, anti-SDHA, anti-Core2, anti-COX IV, and anti-ATP5A, respectively. Actin was used as internal control. Results were representative of three independent experiments. Error bars, ±SD.



Figure S10. BN-PAGE and western blot analysis of whole-cell lysates from digitonin-treated cells. Western blots of control (**left**: 0% m.14487T>C) and patient 2 (**right**: 100% m.14487T>C) samples were probed with anti-Grim19.

| Cell Line | Cell Type | Strain | LSC | Ref. |
|------------|--------------------------------------|---------------------------------------|----------------------|------|
| A9 | fibroblast (areolar and adipose) | C3H/An mouse | $I_n + III_n$ | [45] |
| 3A19 | Lewis Lung | C57BL mouse | $I_n + III_n$ | [20] |
| HIB1B | fibroblasts (brown preadipocytes) | Swiss Webster mouse | In + IIIn | [22] |
| C2C12 | myoblast (muscle) | C3H mouse | $I_n + III_n + IV_n$ | [19] |
| 3T3-L1 | fibroblast (Embryo) | Swiss albino mouse | $I_n + III_n + IV_n$ | [21] |
| Hela | Epithelial (Cervix) | Cervical cancer (African American) | In + IIIn | [46] |
| 143B | osteosarcoma cells | Osteosarcoma (Caucasian) | $I_n + III_n + IV_n$ | [47] |
| MDA-MB-231 | Epithelial (Mammary Gland) | Breast adenocarcinoma (Caucasian) | $I_n + III_n + IV_n$ | [48] |

Table S1. Genetic backgrounds of eight cell lines.

LSC: lowest supercomplex; $I_n + III_n$: respiratory chain supercomplex $I_n + III_n$; $I_n + III_n + IV_n$: respiratory chain supercomplex $I_n + III_n + IV_n$.

Table S2. Analysis of whole mitochondrial genome in patient 1.

| Position | Gene | rCRS Base | Mutation (L) | Mutation (H) | AA Change | mtDNA Databases * |
|----------|----------|-----------|--------------|--------------|-----------|-------------------|
| 73 | D-loop | А | G | G | no | Polymorphic Sites |
| 207 | D-loop | G | А | А | no | Polymorphic Sites |
| 263 | D-loop | А | G | G | no | Polymorphic Sites |
| 502 | D-loop | G | А | А | no | Polymorphic Sites |
| 16136 | D-loop | Т | С | С | no | Polymorphic Sites |
| 16183 | D-loop | А | С | С | no | Polymorphic Sites |
| 16189 | D-loop | Т | С | С | no | Polymorphic Sites |
| 16218 | D-loop | Т | С | С | no | Polymorphic Sites |
| 16310 | D-loop | А | G | G | no | Polymorphic Sites |
| 16355 | D-loop | С | Т | Т | no | Polymorphic Sites |
| 750 | 12s rRNA | А | G | G | no | Polymorphic Sites |
| 827 | 12s rRNA | А | G | G | no | Polymorphic Sites |
| 1438 | 12s rRNA | А | G | G | no | Polymorphic Sites |
| 1719 | 16s rRNA | G | А | А | no | Polymorphic Sites |
| 2220 | 16s rRNA | А | G | G | no | Polymorphic Sites |
| 2706 | 16s rRNA | А | G | G | no | Polymorphic Sites |
| 2831 | 16s rRNA | G | А | А | no | Polymorphic Sites |

| Position | Gene | rCRS Base | Mutation (L) | Mutation (H) | AA Change | mtDNA Databases * |
|----------|---------|-----------|--------------|--------------|-----------|---------------------|
| 3697 | ND1 | G | G | Α | Gly>Ser | Pathogenic Mutation |
| 4769 | ND2 | А | G | G | no | Polymorphic Sites |
| 4820 | ND2 | G | А | А | no | Polymorphic Sites |
| 8860 | ATPase6 | А | G | G | Thr>Ala | Polymorphic Sites |
| 10310 | ND3 | G | А | А | no | Polymorphic Sites |
| 11719 | ND4 | G | А | А | no | Polymorphic Sites |
| 13590 | ND5 | G | А | А | no | Polymorphic Sites |
| 14766 | Cytb | С | Т | Т | Ile>Thr | Polymorphic Sites |
| 15301 | Cytb | G | А | А | no | Polymorphic Sites |
| 15326 | Cytb | А | G | G | Thr>Ala | Polymorphic Sites |
| 15535 | Cytb | С | Т | Т | no | Polymorphic Sites |
| 15754 | Cytb | С | Т | Т | no | Polymorphic Sites |
| 6023 | COXI | G | А | А | no | Polymorphic Sites |
| 6216 | COXI | Т | С | С | no | Polymorphic Sites |
| 6413 | COXI | Т | С | С | no | Polymorphic Sites |
| 7028 | COXI | С | Т | Т | no | Polymorphic Sites |

Table S2. Cont.

* databases: MITOMAP, mtDB and mtSNP; AA: amino acid.